RxDoctor Payments Data

Sonja Bartolome, MD

Pulmonary Disease · Dallas, TXNPI 1013093293

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $59,151 of the $74,856 with a category attached, or 79.0%. 9 manufacturers reported payments, led by Actelion Pharmaceuticals, Ltd at 36.5% of the total. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$74,856in general payments, 2019–2025

Across 102 payments — averaging $733.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals, Ltd$27K
  • Merck$19K
  • United Therapeutics Corporation$14K
  • Bayer$8K
  • Chiesi USA, Inc.$5K
  • Actelion Pharmaceuticals US, Inc.$342
  • plus $535 from 3 others
$348,268in research payments, 2019–2025

Across 100 payments — averaging $3482.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$295K
  • Pfizer$52K
  • Mylan Specialty L.p.$975

What the payments were for

  • Consulting fees$59,15179%
  • Travel & lodging$12,49417%
  • Food & beverage$3,2114%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Actelion Pharmaceuticals, Ltd28$27,337
Merck23$19,346
United Therapeutics Corporation19$14,350
Bayer18$8,193
Chiesi USA, Inc.4$4,753
Actelion Pharmaceuticals US, Inc.3$342
Boehringer Ingelheim3$327
Liquidia Technologies, Inc.2$166
Sandoz2$42

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,856 in reported general payments places this provider in the 90th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$28,831
Medicare patients
123
Services billed
272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan202$2,574,676
AdempasRiociguat60$852,623
UptraviSelexipag35$773,064
Tyvaso DpiTreprostinil13$322,801
WinrevairSotatercept-Csrk20$311,798
Tadalafil110$184,666
Ambrisentan18$107,960
EliquisApixaban46$40,740
Sildenafil Citrate33$14,084
Enoxaparin Sodium14$1,579
Torsemide34$943
Midodrine Hcl12$847
Potassium Chloride38$505
Spironolactone15$217
Furosemide60$176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$342$3,347,740237 claims
BayerAdempas$8,193$852,62360 claims
MerckWinrevair$19,346$311,79820 claims
SandozEnoxaparin Sodium$42$1,57914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →